Curriculum Vitaes
Profile Information
- Affiliation
- Designated associate professor, School of Medicine, Fujita Health University
- Degree
- 博士(医学)(名古屋市立大学)博士(法学)(名古屋大学)
- J-GLOBAL ID
- 201001020199616390
- researchmap Member ID
- 6000026153
- External link
Research Areas
1Research History
17-
Apr, 2023 - Present
-
Apr, 2022 - Present
-
Apr, 2021 - Present
-
Apr, 2017 - Present
-
Apr, 2015 - Present
Education
5-
Mar, 2016
-
Apr, 2004 - Mar, 2006
-
Apr, 2002 - Mar, 2004
-
Apr, 1982 - Mar, 1988
Committee Memberships
17-
Apr, 2025 - Present
-
Apr, 2025 - Present
-
Apr, 2023 - Present
-
Apr, 2023 - Present
-
Apr, 2023 - Present
Papers
39-
Nagoya J. Med. Sci., 85 797-806, Nov, 2023 Lead authorLast author
-
臨床薬理, 53(5) 159-167, Sep, 2022 Peer-reviewed
-
Nagoya Journal of Medical Science, Mar, 2022 Peer-reviewedLead authorCorresponding author
-
Nagoya Journal of Medical Science, 83(2) 299-309, May, 2021 Peer-reviewedLead authorCorresponding authorIn 2018, we conducted a study on 121 ethics review committee offices in Japan to examine the state of "central review" in non-interventional studies and discern any challenges regarding its introduction. Of the 452 offices that were invited to participate, 121 responded (26.8% response rate), and 35 (28.9%) had records of furnishing contracting agreements with ethical reviews by other research institutions. The merits of central reviewing include easing the burden on ethics review committees, improving the quality level and consistency of ethical reviews, and enhancing the efficiency in conducting them. The demerits include increased administrative overheads and work for researchers, such as preparing application forms and checking institutional requirements, and a lack of clarity regarding who is responsible for conducting the research, which makes it is less desirable for institutions to have their own ethics review committees. This study revealed that the comprehensive introduction of central review in non-interventional studies continues to encounter many hurdles, and promoting central review requires overcoming these challenges one at a time. The Ethical Guidelines for Medical and Health Research Involving Human Subjects will be revised in 2021 to require central review as a part of ethical reviews for non-interventional studies. In the future, central reviews of non-interventional studies will need to be of high quality and conducted efficiently, and this will require research institutions to utilize relevant central review guidelines and checklists.
-
Journal of law and medicine, 27(4) 981-984, Aug, 2020 Lead authorCorresponding authorClinical issues involving ethical dilemmas arise daily and confound physicians as they provide medical care. These dilemmas require difficult decisions as physicians must respect patients' values, lifestyles, and freedom of choice while protecting life and promoting health. This is made more challenging as values and lifestyles become more diverse, making third-party support necessary to accommodate the wishes of stakeholders, particularly patients. Collaborative work is important for addressing clinical ethics issues. Government agencies and professional organisations should discuss individual cases as public policy concerns and release guidelines based on their deliberations. Medical institutions should refer to such guidelines in their own discussions on ethically challenging cases. This is not the case today as each organisation creates its own guidelines; there is no consensus on how clinical ethics committees or consultations should be conducted. Support systems that are public in nature are needed to protect patients' rights and freedoms in medical care.
-
Nagoya journal of medical science, 82(2) 193-204, May, 2020 Lead authorCorresponding authorWe investigated the differences in Japanese and United States medical and legal professional opinions on ethical support for clinical ethical issues using the refusal of blood transfusions on the grounds of religious principles as an example of a clinical ethical issue. In ethical support systems for medical institutions in Japan, 95.0% of "clinical training designation hospitals" have hospital ethics committees, and 63.1% have medical safety divisions; clinical ethical support is provided in accordance with their scale and function. In terms of clinical ethical support limits the discretion of physicians, 59.2% of lawyers responded "No" and 54.4% of doctors responded "Yes". In addition, on the feasibility of government or academic guidelines in clinical practice, 37.7% of lawyers responded "Yes" and 63.0% of doctors responded "No". In terms of "relative transfusion-free" policy, 83.2% of lawyers and 76.8% of doctors responded that it is "unavoidable," while 81.6% of U.S. committee heads responded that it is a "violation of rights." In terms of hospital transfers due to a hospital being unable to treat patients refusing blood transfusion, 62.6% of lawyers reported that it is "unavoidable" while 57.1% of U.S. committee heads reported that it "should be avoided". The results of this study indicate that medical and legal professionals and U.S. ethics committee heads recognize clinical ethical issues in slightly different ways.
-
Nagoya journal of medical science, 81(3) 501-509, Aug, 2019 Peer-reviewedLead authorCorresponding authorThe survey involves examining the applications from 142 institutions that have consented to make available all certification applications from 2015 and 2016 to a research project for building a certification system for an ethics committee run by the Agency for Medical Research and Development. The number of certified institutions is 20 (14.1%). In the applications from uncertified institutions, there are cases in which requirements of ethics guidelines are unmet, and there is insufficient information provided on regulation and procedure. An analysis of the committee members who can contribute as members of the general public (general public committee members) has indicated that the number of committee members who do not belong to an institution in which an ethics committee is instituted (external committee members) is 41 (95.7%) among the certified institutions and 224 (84.5%) among the uncertified institutions. The proportion of general public committee members drawn internally from institutions tends to be higher among uncertified institutions. While a separate committee examined conflicts of interest in research in 19 certified institutions (95.0%), such conflicts were found in 41 uncertified institutions (33.9%) by the ethics committee. The survey confirms that the challenge lies in increasing the number of external committee members and in further improving the system to manage conflicts of interest, and the education and training regime.
-
Japan Journal of Medicine, 1(3) 183-185, Jun 30, 2018 Peer-reviewedLead authorCorresponding author
-
生命倫理, 27(1) 79-86, Sep, 2017 Peer-reviewedLead authorCorresponding author
-
臨床倫理, (4) 17-22, Sep, 2016 Peer-reviewedLead authorCorresponding author
-
精神経誌, 118(5) 351-357, May, 2016 Lead authorCorresponding author
-
生命倫理, 25(1) 30-37, Dec, 2015 Peer-reviewedLead authorLast authorCorresponding author
-
分子精神医学, 13(1) 12-17, Jan, 2013 InvitedLead authorCorresponding author
-
PSYCHIATRY AND CLINICAL NEUROSCIENCES, 65(5) 535-536, 2011 Peer-reviewedLead author
-
Clinical Neurology, 51(11) 830-833, 2011 Peer-reviewed
-
Nagoya journal of medical science, 71(1-2) 63-69, Feb, 2009 Peer-reviewedLead authorCorresponding author
-
Journal of Gastroenterology and Hepatology, 16 782-788, 2001 Peer-reviewedLead author
-
Asian Pacific J Cancer Prev,, 1 237-242, 2000 Peer-reviewed
-
Journal of Hepatology, 31(2) 221-227, Aug, 1999 Peer-reviewed
-
Journal of Gastroenterology and Hepatology, 12(1) 58-61, Jan, 1997 Peer-reviewed
-
Japanese Journal of Cancer and Chemotherapy, 23(4) 483-486, 1996
Misc.
42Books and Other Publications
5Presentations
44Teaching Experience
10Professional Memberships
10Research Projects
7-
科学研究費助成事業, 日本学術振興会, Apr, 2023 - Mar, 2027
-
民事紛争処理研究基金研究助成, 民事紛争処理研究基金, Jul, 2022 - Mar, 2025
-
障害者対策総合研究開発事業(精神障害分野), 日本医療研究開発機構, Jul, 2022 - Mar, 2025
-
再生・細胞治療・遺伝子治療実現加速化プログラム, 日本医療研究開発機構(AMED), Jun, 2024
-
厚生労働省, Jul, 2020 - Mar, 2023